# 617839

AMYOTROPHIC LATERAL SCLEROSIS 23; ALS23


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
10q22.3 Amytrophic lateral sclerosis 23 617839 AD 3 ANXA11 602572
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
NEUROLOGIC
Central Nervous System
- Amyotrophic lateral sclerosis
- Upper motor neuron involvement
- Lower motor neuron involvement
- No dementia
MISCELLANEOUS
- Average age at onset 67 years
- Incomplete penetrance
MOLECULAR BASIS
- Caused by mutation in the annexin A11 gene (ANXA11, 602572.0001)
Amyotrophic lateral sclerosis - PS105400 - 35 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia AD 3 616208 TUBA4A 191110
3p11.2 Amyotrophic lateral sclerosis 17 AD 3 614696 CHMP2B 609512
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} AD 3 617892 NEK1 604588
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 3 613954 VCP 601023
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 3 613435 OPTN 602432
10q22.3 Amytrophic lateral sclerosis 23 AD 3 617839 ANXA11 602572
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q13.3 {Amyotrophic lateral sclerosis, susceptibility to, 25} AD 3 617921 KIF5A 602821
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPB 605704
21q22.11 Amyotrophic lateral sclerosis 1 AR, AD 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 ?{Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia 205200 ALSDC 205200

TEXT

A number sign (#) is used with this entry because of evidence that amyotrophic lateral sclerosis-23 (ALS23) is caused by heterozygous mutation in the ANXA11 gene (602572) on chromosome 10q22.

For a phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Smith et al. (2017) reported 10 patients from 7 unrelated families with familial ALS and 3 unrelated patients with sporadic ALS associated with ANXA11 mutations. The patients had late onset (range, 50 to 83 years; average, 67 years) of classic ALS disease symptoms without dementia, and both bulbar and limb onset occurred. Postmortem examination of 1 patient showed marked neuronal loss within the anterior horn of the spinal cord and myelin pallor and astrogliosis in the anterior and lateral corticospinal tracts. Many surviving motor neurons contained cytoplasmic inclusions that stained positive for p62 (601530) and TDP43 (605078).


Inheritance

The transmission pattern of ALS23 in the families reported by Smith et al. (2017) was consistent with autosomal dominant inheritance with incomplete penetrance.


Molecular Genetics

In 10 patients from 7 unrelated families with ALS23, Smith et al. (2017) identified 4 different heterozygous missense mutations in the ANXA11 gene (see, e.g., D40G, 602572.0001, G38R, 602572.0002; and G175R, 602572.0003). Three patients with sporadic ALS were also found to carry heterozygous missense variants (D40G, G189E, and R235Q). The mutations were found by whole-exome sequencing of 751 probands with familial ALS (FALS) and direct sequencing of the ANXA11 gene in 180 patients with sporadic ALS. (Elsewhere in the paper, the FALS cohort is noted to include 694 probands). One recurrent mutation, D40G, was found in 3 families and in 1 patient with sporadic ALS; haplotype analysis suggested that the mutation arose on a European background. Four of the 6 mutations identified clustered in the long N terminus, suggesting functional importance. Postmortem tissue available from a patient with the D40G mutation showed classic pathologic features of ALS and large neuronal cytoplasmic ANXA11-immunoreactive inclusions in the spinal cord and certain brain regions, including the motor cortex and occipital lobe. These aggregates formed skein-like, tubular-shaped, filamentous, and complex basket-like structures. These inclusions did not colocalize with TDP43. ANXA11 inclusions were not observed in controls or in patients with other neurodegenerative disorders. Overexpression of mutant ANXA11 in mouse and human cells showed that the R235Q mutant caused increased aggregation, whereas other variants did not. R235Q sequestered wildtype ANXA11 into inclusions, consistent with a dominant-negative effect. Calcyclin binding was inhibited by the D40G, G189E, and R235Q mutations, but was increased by the G38R mutation compared to wildtype. Smith et al. (2017) speculated that loss of calcyclin binding may result in an accumulation of cytoplasmic annexin A11, promoting formation of insoluble aggregates and likely disrupting intracellular protein trafficking.


REFERENCES

  1. Smith, B. N., Topp, S. D., Fallini, C., Shibata, H., Chen, H.-J., Troakes, C., King, A., Ticozzi, N., Kenna, K. P., Soragia-Gkazi, A., Miller, J. W., Sato, A., and 44 others. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med. 9: eaad9157, 2017. Note: Electronic Article. [PubMed: 28469040, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 01/19/2018
carol : 01/30/2018
carol : 01/29/2018
ckniffin : 01/26/2018

# 617839

AMYOTROPHIC LATERAL SCLEROSIS 23; ALS23


ORPHA: 803;   DO: 0080225;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
10q22.3 Amytrophic lateral sclerosis 23 617839 Autosomal dominant 3 ANXA11 602572

TEXT

A number sign (#) is used with this entry because of evidence that amyotrophic lateral sclerosis-23 (ALS23) is caused by heterozygous mutation in the ANXA11 gene (602572) on chromosome 10q22.

For a phenotypic description and a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Smith et al. (2017) reported 10 patients from 7 unrelated families with familial ALS and 3 unrelated patients with sporadic ALS associated with ANXA11 mutations. The patients had late onset (range, 50 to 83 years; average, 67 years) of classic ALS disease symptoms without dementia, and both bulbar and limb onset occurred. Postmortem examination of 1 patient showed marked neuronal loss within the anterior horn of the spinal cord and myelin pallor and astrogliosis in the anterior and lateral corticospinal tracts. Many surviving motor neurons contained cytoplasmic inclusions that stained positive for p62 (601530) and TDP43 (605078).


Inheritance

The transmission pattern of ALS23 in the families reported by Smith et al. (2017) was consistent with autosomal dominant inheritance with incomplete penetrance.


Molecular Genetics

In 10 patients from 7 unrelated families with ALS23, Smith et al. (2017) identified 4 different heterozygous missense mutations in the ANXA11 gene (see, e.g., D40G, 602572.0001, G38R, 602572.0002; and G175R, 602572.0003). Three patients with sporadic ALS were also found to carry heterozygous missense variants (D40G, G189E, and R235Q). The mutations were found by whole-exome sequencing of 751 probands with familial ALS (FALS) and direct sequencing of the ANXA11 gene in 180 patients with sporadic ALS. (Elsewhere in the paper, the FALS cohort is noted to include 694 probands). One recurrent mutation, D40G, was found in 3 families and in 1 patient with sporadic ALS; haplotype analysis suggested that the mutation arose on a European background. Four of the 6 mutations identified clustered in the long N terminus, suggesting functional importance. Postmortem tissue available from a patient with the D40G mutation showed classic pathologic features of ALS and large neuronal cytoplasmic ANXA11-immunoreactive inclusions in the spinal cord and certain brain regions, including the motor cortex and occipital lobe. These aggregates formed skein-like, tubular-shaped, filamentous, and complex basket-like structures. These inclusions did not colocalize with TDP43. ANXA11 inclusions were not observed in controls or in patients with other neurodegenerative disorders. Overexpression of mutant ANXA11 in mouse and human cells showed that the R235Q mutant caused increased aggregation, whereas other variants did not. R235Q sequestered wildtype ANXA11 into inclusions, consistent with a dominant-negative effect. Calcyclin binding was inhibited by the D40G, G189E, and R235Q mutations, but was increased by the G38R mutation compared to wildtype. Smith et al. (2017) speculated that loss of calcyclin binding may result in an accumulation of cytoplasmic annexin A11, promoting formation of insoluble aggregates and likely disrupting intracellular protein trafficking.


REFERENCES

  1. Smith, B. N., Topp, S. D., Fallini, C., Shibata, H., Chen, H.-J., Troakes, C., King, A., Ticozzi, N., Kenna, K. P., Soragia-Gkazi, A., Miller, J. W., Sato, A., and 44 others. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med. 9: eaad9157, 2017. Note: Electronic Article. [PubMed: 28469040] [Full Text: http://stm.sciencemag.org/cgi/pmidlookup?view=short&pmid=28469040]


Creation Date:
Cassandra L. Kniffin : 01/19/2018
Edit History:
carol : 01/30/2018
carol : 01/29/2018
ckniffin : 01/26/2018